Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00240370 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,159
- Enrollment target
NCT00240370: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT00240370 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,159 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (50% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00240370, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,159 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate if type 2 diabetics who have inadequate glycemic control on metformin alone, have a similar, or not inferior, glycemic response when treated with the combination of muraglitazar and metformin compared to pioglitazone and metformin.
Interventions
- DRUG Muraglitazar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,159 participants |
| Start Date | 2003-10 |
| Phase | Phase 3 |
What the finished NCT00240370 record still lists
NCT00240370 is an interventional study that assigns participants to a tested intervention. Its 1,159 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (50% higher).
The record links to 0 conditions, and to 1 intervention - of which Muraglitazar is the first listed.
NCT00240370 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00240370 about?
NCT00240370 is a clinical study titled "A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics". The purpose of this study is to evaluate if type 2 diabetics who have inadequate glycemic control on metformin alone, have a similar, or not inferior, glycemic response when treated with the combination of muraglitazar and metformin compared to pioglitazone and metformin.
What is the current status of trial NCT00240370?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,159 participants. The study started on 2003-10.
What interventions are being tested in trial NCT00240370?
The interventions under investigation include: Muraglitazar (DRUG).
Who is sponsoring clinical trial NCT00240370?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00240370's enrollment target sits among peer trials
1,159 238th of 2000 higher than 1,763 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04577599 · 1,160 participants · NA
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
- NCT07082738 · 1,160 participants · Phase 2
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- NCT07237048 · 1,164 participants · Phase 2
Minocycline in Stroke Study at Maimonides
- NCT07009509 · 1,166 participants · NA
Pilot Study of the YES-CAN! Program to Prevent Youth Nicotine Vaping
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia